Dr. Patrick Hemmons travelled to Seattle to get an RSV shot for his daughter. He says he hopes to see nirsevimab become more ...

Karen B. Jacobson, M.D., M.P.H., from Kaiser Permanente Northern California in Oakland, and colleagues investigated the ...

Nearly 80% of infants born in a California health system were exposed to nirsevimab or the maternal respiratory syncytial ...

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

More information: Heidi L. Moline et al, Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024, JAMA Pediatrics (2024). DOI: 10.1001 ...

Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and ...

The price you pay for Beyfortus may depend on factors such as your child’s dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Beyfortus.

Jacobson, MD, MPH, from Kaiser Permanente Northern California in Oakland, and colleagues investigated uptake of RSVpreF among pregnant women at 32 to 36 weeks of gestation and nirsevimab among ...